ABSTRACT
. Clinical classification of pulmonary hypertension, as proposed at the Fourth World Symposium on Pulmonary Hypertension in 2008. as "pre-capillary, " arising from vasoconstriction; "post-capillary" or "passive, " arising from excessive intravascular volume; or "mixed, "
Pulmonary arterial hypertension (PAH)
arising from vascular remodeling, which result in increased pulmonary capillary resistance and increased intravascular volume (Table 1) . 1 Therapeutic interventions designed to alleviate symptoms arising from WHO group II PH should target specific etiology, which illustrates the importance of understanding which component is particularly prominent in the PH pathophysiology.
The focus of this review is the monitoring of PH heart disease, particularly with the use of implantable hemodynamic monitors (IHMs).
Pulmonary Hypertension Management Rationale for Pharmacological Therapy
Left-sided heart failure (HF), the most common cause of 
Rationale for Device Therapy
Despite significant reductions in overall mortality rates and progression of disease through neurohormonal intervention, the incidence of malignant, potentially lethal arrhythmias remains high, especially in those with HFrEF (LVEF < 35%). Clinical trials that intend to address the unacceptably high rate of sudden arrhythmic death were developed especially after implantable cardioverter defibrillators (ICDs) became smaller and easier to implant. Mortality reductions were consistently observed across a wide range of patients with HFrEF initially described as LVEF < 30% and associated with coronary artery disease but subsequently broadened to include patients with LVEF < 35% due to any etiology. Subsequently, it became clear that ICDs, once implanted, simply monitor for potentially lethal arrhythmias with the intention of early termination to prevent sudden death. This device therapy may increase hospitalizations and has no effect on HF disease progression. Therefore, this clarifies that the "value" of 
Current Pulmonary Hypertension Monitoring
A successful ambulatory monitoring strategy should take into 
Impedance-based IHM
With more than 300,000 ICD systems implanted each year, signals can be wirelessly downloaded from the implant by a handheld unit by using ultrasound, enabling remote monitoring.
The safety and feasibility of the device were demonstrated by the
PAPIRUS (Pulmonary Artery Pressure by Implantable device
Responding to Ultrasonic Signal) II clinical study, which revealed no serious adverse events and accuracy relative to a high fidelity pressure catheter over 6 months. 9 The clinical benefit of this PA pressure monitor is currently being evaluated in the PAPIRUS III trial.
The Chronicle system shares an overall design and delivery technique to the traditional pacemaker, and has a pectoral case connected to a tined RV lead equipped with an intraventricular pressure sensor (Figure 1 ). The pressure-sensitive capacitor in the sensor measures RV Ps, Pd, and PP, which can be used to estimate PA Pd. In addition, the lead tip electrode provides electrograms and HR that are used to detect bradyarrhythmias and tachyarrhythmias. These metrics, including body temperature and activity level, are continuously monitored and stored in device memory. Data can be wirelessly downloaded to external transmission units and sent to clinicians for potential adjustments to treatment. The accuracy of Chronicle pressures, relative to measurements via right heart catheterization, has been demonstrated in several small-scale studies. [10] [11] [12] In addition, the device was successfully used to quantify the short-and long-term effects of multiple hypertension medications. 13, 14 In terms of safety, the COMPASS-HF study demonstrated negligible sensor failures and device-related complications. 15 In terms of clinical efficacy, the device showed a 21% reduction in HF-related hospitalization, which is greater than that by optimal medical therapy alone. 15 The HeartPOD™ system directly measures LAP with a pressure sensor-tipped lead that is transseptally introduced from the RA into the LA, and fixed with nitinol anchors at the septum. Like
Chronicle, this system was also modeled after the traditional pacemaker. The lead is connected to a pectoral case that includes an antenna coil for wireless radiofrequency transmissions to an external handheld unit. The HOMEOSTASIS (Hemodynamically Guided Home Self-Therapy in Severe Heart Failure Patients) trial showed low rates of device failure (5% at 2 yr and 12% at 4 yr) and strong concordance with the standard LAP estimation technique, which measures pulmonary capillary wedge pressure by using a Swan-Ganz catheter. 16 Long-term efficacy is CardioMEMS™, like Chronicle, provides right-side heart pressures. However, the PA Pd waveform that is provided by both devices can be used to estimate downstream LA pressures. 17 In terms of safety, the CHAMPION (CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in NYHA Class III Patients) trial demonstrated negligible sensor failures and device-related complications, similar to Chronicle. 18 In terms of clinical efficacy, the device showed a 39% reduction in HF-related hospitalization at 15 months, which is greater than that by optimal medical therapy alone. 18 Patients with confirmed secondary PH also benefitted from remote monitoring of PA pressures in the CHAMPION trial. 19 Patients with PH were at higher risk of adverse events and mortality, but treatment group outcomes were better than those in the control group during the entire follow-up of the trial. 
